Cargando…

Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction

Type 2 diabetes is an increasingly common comorbidity of stage C heart failure with reduced ejection fraction (HFrEF). The two diseases are risk factors for each other and can bidirectionally independently worsen outcomes. The regulatory requirement of cardiovascular outcomes trials for antidiabetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwalla, Anjali, Gruen, Jadry, Peters, Carli, Sinnenberg, Lauren, Owens, Anjali T, Reza, Nosheen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006126/ https://www.ncbi.nlm.nih.gov/pubmed/35433030 http://dx.doi.org/10.15420/cfr.2021.31

Ejemplares similares

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Cell Therapy in Heart Failure with Preserved Ejection Fraction
por: Frljak, Sabina, et al.
Publicado: (2022)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap
por: Reza, Nosheen, et al.
Publicado: (2022)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction
por: Vrtovec, Bojan, et al.
Publicado: (2022)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and the Role of Percentage of Delayed Enhancement Measured by Cardiac Magnetic Resonance in Predicting Therapeutic Response: A Multicentre Study
por: Nugara, Cinzia, et al.
Publicado: (2023)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Endpoints in Heart Failure Drug Development
por: Hussain, Aliza, et al.
Publicado: (2022)

Role of interleukins in heart failure with reduced ejection fraction
por: Segiet, Oliwia Anna, et al.
Publicado: (2019)

Updates in pharmacotherapy of heart failure with reduced ejection fraction
por: Espinoza, Clifton, et al.
Publicado: (2021)

Editorial: Edema in heart failure with reduced ejection fraction
por: Gladysheva, Inna P., et al.
Publicado: (2023)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction
por: Shahnazaryan, Syuzanna, et al.
Publicado: (2023)

Heart Failure With Preserved Ejection Fraction vs. Reduced Ejection Fraction　― Mechanisms of Ventilatory Inefficiency During Exercise in Heart Failure ―
por: Tsujinaga, Shingo, et al.
Publicado: (2020)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
por: Sharma, Abhinav, et al.
Publicado: (2022)

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?
por: Raffaello, Wilson Matthew, et al.
Publicado: (2021)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature
por: Techorueangwiwat, Chol, et al.
Publicado: (2021)

Prognosis of patients with heart failure and reduced ejection fraction in China
por: XU, YU, et al.
Publicado: (2013)

The concentration of interleukin-33 in heart failure with reduced ejection fraction
por: Anna Segiet, Oliwia, et al.
Publicado: (2019)

Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction
por: Al‐Mohammad, Abdallah
Publicado: (2019)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
por: Rossitto, Giacomo, et al.
Publicado: (2020)

Heart failure with reduced ejection fraction due topolycythemia vera
por: Zaman, Muhammad Omer, et al.
Publicado: (2021)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
por: Swaraj, Sascha, et al.
Publicado: (2021)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021)

Medical Management of Patients With Heart Failure and Reduced Ejection Fraction
por: Greenberg, Barry
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s289ttc265nk1n7hqane8m674q